Top Markets
Coin of the day
Annovis Bio, Inc. Annovis Bio, Inc.

Annovis Bio, Inc.

ANVS
Classifica tra le azioni #23205
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on... Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases. This compound is also currently being evaluated in clinical studies for Alzheimer's disease in individuals with Down Syndrome, as well as for various other chronic neurodegenerative conditions. Beyond Buntanetap, Annovis Bio is developing ANVS405 to offer protection against traumatic brain injury and stroke. Additionally, ANVS301 is progressing through Phase I clinical trials, aiming to enhance cognitive capabilities in the later stages of Alzheimer's disease and broader dementia. The company was founded in 2008 and operates out of Berwyn, Pennsylvania.
Prezzo delle azioni
$1.81
Ultima sincronizzazione: 2026-08-21
Capitalizzazione di mercato
$77.00M
Variazione (1 giorno)
1.30%
Variazione (1 anno)
-23.63%
Paese
US
Scambia Annovis Bio, Inc. (ANVS)

Categoria

Storico del prezzo dell'azione per Annovis Bio, Inc. (ANVS)
Prezzo di chiusura più alto: $1.82 il 2026-08-01

Prezzo di chiusura più basso: $7.71 il 2020-01-01
Storico del prezzo dell'azione di Annovis Bio, Inc. dal 2020 al 2026
Andamento annuale del prezzo dell'azione
Anno Performance
2026 (TTM) -38.81%
2025 -26.28%
2024 -55.51%
2023 0.70%
2022 -41.39%
2021 233.32%
2020 0.00%
Prezzo dell'azione per aziende simili o concorrenti
Azienda Prezzo dell'azione Variazione 1a% Il paese
$547.71 38.62%
US
$1.04K 58.06%
NL
$145.75 437.43%
US
$118.70 -15.60%
AU
$770.19 8.98%
CH